MET and glioblastoma: Furthermore, the in-vitro experiment results indicated that the knockdown of c-MET could decrease the survival (Figure 11A) and proliferation (Figure 11B) of glioblastoma cell line ln299, which could be further enhanced by the combination treatment with cabozantinib (2μM, a c-MET inhibitor) (Figures 11A, B).